Voriconazole for invasive pulmonary aspergillosis

Abstract

Objective To observe the clinical efficacy of voriconazole in the empirical treatment of invasive pulmonary aspergillosis and to guide the clinical medication.Methods 65 inpatients with invasive pulmonary aspergillosis receiving voriconazole treatment in our hospital from January 2010 to October 2012 were collected and then were divided into an empirical treatment group (35 cases) and,a target treatment group (30 cases).The empirical treatment group were suspected with invasive pulmonary aspergillosis before sputum culture results and were immediately treated with voriconazole(Jincheng Pharmaceutical Hayes) 6 mg/kg once every 12h on day 1 then 4 mg/kg twice daily.The target treatment group were treated with voriconazole in the same way after being confirmed with invasive pulmonary aspergillosis.Results The effective rate and the mortality rate were 51.43％ and 23.33％ in the empirical treatment group and were 22.86％ and 46.67％ in the target treatment group,with statistical differences (P=0.020,P=0.040).The adverse effect rate was 20.00％ in the empirical treatment group and was 16.67％ in the target treatment group,with no statistical difference (P=0.73).The effective rate was 53.13％ in the empirical treatment group and was 22.22％ in the target treatment group,with a statistical difference (P=0.015).Conclusions Voriconazole can be used as empirical treatment for invasive pulmonary aspergillosis,which can improve the effective rate in clinical treatment and reduce mortality.Especially for patients with high risk factors,voriconazole can significantly improve the effective rate. Key words: Voriconazole; Invasive pulmonary aspergillosis; Empirical treatment